Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.32 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.32 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | CCR8 | P51685 | 1/20 | 0.31 |
| ▸ | METAP1 | P53582 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.31 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL295632 | 0.80 | EHMT2 (0.48) | EHMT2EHMT1APOBEC3GKMT2AKDM4E | |
| SCHEMBL2423602 | 0.79 | — | — | |
| SCHEMBL3145115 | 0.73 | DDAH1 (0.50) | KMT2ALMNACYP1A2HIF1AMAPT | |
| SCHEMBL10767567 | 0.73 | HTT (0.45) | HSD17B10APOBEC3GKMT2ASMN1; SMN2LMNA | |
| SCHEMBL924231 | 0.73 | MTOR (0.36) | — | |
| SCHEMBL440187 | 0.72 | — | — | |
| SCHEMBL3145761 | 0.72 | FBP1 (0.44) | SMN1; SMN2GAA | |
| SCHEMBL237661 | 0.71 | HPGD (0.38) | HSD17B10SMN1; SMN2KDM4EMAPTMAPK1 | |
| SCHEMBL980439 | 0.70 | — | — | |
| SCHEMBL3145825 | 0.69 | GRM5 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113979917-A | Trimethine cyanine dye, synthesis method and application | 南京大学 | 2022-01-28 | — | — | CN | claimed |
| CN-106910831-B | Organic light emitting device | 三星显示有限公司 | 2020-05-05 | — | — | CN | claimed |
| EP-2875018-A1 | FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEX | Cleave Biosciences, Inc. (US) | 2015-05-27 | — | — | EP | claimed |
| US-20140024661-A1 | FUSED PYRIMIDINES AND SUBSTITUTED QUINAZOLINES AS INHIBITORS OF P97 | CLEAVE BIOSCIENCES, INC. (US) | 2014-01-23 | — | — | US | claimed |
| WO-2014015291-A1 | FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEX | ZHOU HAN-JIE (US) | 2014-01-23 | — | — | WO | claimed |
| EP-2311842-A2 | PI3K/M TOR inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2011-04-20 | — | — | EP | claimed |
| EP-2303886-A2 | PI3K/M TOR INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2011-04-06 | — | — | EP | claimed |
| WO-2010008847-A2 | PI3K/M TOR INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-21 | — | — | WO | claimed |
| EP-1027056-B1 | ALPHA-KETOAMIDE MULTICATALYTIC PROTEASE INHIBITORS | CEPHALON INC (US) | 2009-02-25 | — | — | EP | claimed |
| US-5696243-A | HEAT AND OXIDATION RESISTANCE | GASF AKTIENGESELLSCHAFT (DE) | 1997-12-09 | — | — | US | claimed |
| CN-110835333-B | Benzimidazole substituted azole compound and application thereof | 中国药科大学 | 2022-10-18 | — | — | CN | disclosed |
| CN-110835334-B | Indole-substituted azole compound and application thereof | 中国药科大学 | 2022-10-18 | — | — | CN | disclosed |
| CN-110835336-B | Oxygen-containing heterocyclic substituted azole compound and application thereof | 中国药科大学 | 2022-10-04 | — | — | CN | disclosed |
| CN-108690006-B | Compound and application thereof in anti-AML (AML) drugs | 中国药科大学 | 2022-02-18 | — | — | CN | disclosed |
| CN-113979917-A | Trimethine cyanine dye, synthesis method and application | 南京大学 | 2022-01-28 | — | — | CN | disclosed |
| US-6096778-A | A PEPTIDE DERIVATIVE USEFUL FOR THE TREATMENT OF MUSCLE WASTING DISORDERS | CEPHALON, INC. (US) | 2000-08-01 | — | — | US | disclosed |
| EP-1021199-A1 | PEPTIDE-CONTAINING $g(a)-KETOAMIDE CYSTEINE AND SERINE PROTEASE INHIBITORS | CEPHALON, INC. (US) | 2000-07-26 | — | — | EP | disclosed |
| WO-1999017778-A1 | α-KETOAMIDE MULTICATALYTIC PROTEASE INHIBITORS | CEPHALON INC. (US) | 1999-04-15 | — | — | WO | disclosed |
| WO-1999017790-A1 | PEPTIDE-CONTAINING α-KETOAMIDE CYSTEINE AND SERINE PROTEASE INHIBITORS | CEPHALON INC. (US) | 1999-04-15 | — | — | WO | disclosed |
| US-5696243-A | HEAT AND OXIDATION RESISTANCE | GASF AKTIENGESELLSCHAFT (DE) | 1997-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024661-A1 | FUSED PYRIMIDINES AND SUBSTITUTED QUINAZOLINES AS INHIBITORS OF P97 | PSMG3, PSMD1, PSMD3 | HSD17B10 3745/4885EHMT2 4241/4885EHMT1 4267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.